Development and validation of the COVID-NoLab and COVID-SimpleLab risk scores for prognosis in 6 US health systems

Mark H. Ebell MD, MS (1)
Xinyan Cai, MPH (1) [Xinyan.Cai@uga.edu]
Robert Lennon MD (2) [rlennon@pennstatehealth.psu.edu]
Derjung M. Tarn, MD, PhD (3) [DTarn@mednet.ucla.edu]
Arch G. Mainous III, PhD (4) [arch.mainous@phhp.ufl.edu]
Aleksandra E. Zgierska MD, PhD (5) [azgierska@pennstatehealth.psu.edu]
Bruce Barrett MD, PhD (6) [bruce.barrett@fammed.wisc.edu]
Wen-Jan Tuan, DHA MS MPH (6) [Wen-Jan.Tuan@fammed.wisc.edu]
Kevin Maloy MD (7) [Kevin.R.Maloy@Medstar.net]
Munish Goyal MD (7) [Munish.Goyal@gunet.georgetown.edu]
Alex Krist MD, MPH (8) [ahkrist@vcu.edu]

1. Department of Epidemiology and Biostatistics, College of Public Health, University of Georgia, Athens, GA, USA.
2. Department of Family and Community Medicine, Penn State College of Medicine, Hershey, PA, USA.
3. Department of Family Medicine, David Geffen School of Medicine at UCLA, University of California - Los Angeles, Los Angeles, CA, USA
4. Department of Health Services Research, Management and Policy, University of Florida, USA
5. Departments of Public Health Sciences, and Anesthesiology and Perioperative Medicine, Penn State College of Medicine, Hershey, PA, USA.

© Copyright 2020 by the American Board of Family Medicine.
Ahead-of-print; non-copy edited version.
6. Department of Family Medicine and Community Health, University of Wisconsin, Madison, WI, USA

7. Department of Emergency Medicine, MedStar Washington Hospital Center, Washington DC, USA

8. Department of Family Medicine, Virginia Commonwealth University, Richmond VA, USA

**Corresponding Author**

Mark H. Ebell MD, MS

125 BS Miller Hall

UGA Health Sciences Campus

Athens, GA 30602

[ebell@uga.edu](mailto:ebell@uga.edu)

706-247-4953

Word Count: 2743 words, 5 tables, 1 online appendix.

Abstract: 241 words

**Funding:** None

**Conflict of Interest:** None
Abstract

Purpose: To develop and validate simple risk scores based on initial clinical data and no or minimal laboratory testing to predict mortality in hospitalized adults with COVID-19.

Methods: We identified consecutive inpatients with COVID-19 who had either died or been discharged alive at six US health centers and gathered clinical and initial laboratory variables at admission. Data were divided into derivation and validation groups. Logistic regression was used to develop two predictive models, one using no laboratory values (COVID-NoLab) and one adding tests available in many outpatient settings (COVID-SimpleLab). The regression models were converted to point scores and their accuracy evaluated in the validation group.

Results: We identified 1340 adult inpatients who had complete data for non-laboratory parameters and 741 who had complete data for white blood cell count (WBC), differential, c-reactive protein (CRP), and serum creatinine. The COVID-NoLab risk score includes age, respiratory rate, and oxygen saturation and identified risk groups with 0.8%, 11.4% and 40.4% mortality in the validation group (AUROC=0.803). The COVID-SimpleLab risk score includes age, respiratory rate, oxygen saturation, WBC, CRP, serum creatinine and comorbid asthma, and identified risk groups with 1.0%, 9.1%, and 29.3% mortality in the validation group (AUROC=0.833). Calibration of both models was good.

Conclusions: We developed and internally validated two simple risk scores for hospitalized patients that require either no or minimal laboratory testing. Due to their limited data requirements these risk scores have potential applicability in the outpatient setting, but require prospective validation in that setting before being used.
Introduction

The COVID-19 pandemic caused by the SARS-CoV-2 virus, named COVID-19, has created an unprecedented health crisis. There have been over 10 million confirmed cases and over 500,000 deaths worldwide, with an estimated 10 undetected cases per confirmed case. The case fatality rate is estimated to be approximately 0.5 to 1.0%, approximately 5 to 10 times higher than seasonal influenza, with older patients having much higher case fatality rates. The spectrum of illness is broad, ranging from completely asymptomatic carriers to those with critical illness and death. This breadth of presentation makes optimal disposition difficult at the time of initial presentation, since the clinical presentation may not correlate with the patient's actual risk of a bad outcome.

A major concern is that hospital beds and in particular intensive care unit (ICU) beds and mechanical ventilators may be overwhelmed when cases rise in an area. This makes it critical that physicians have the tools needed to identify patients both at lower and elevated mortality risk at the time of initial presentation. An accurate risk assessment tool using simple parameters available on presentation to the emergency department (ED) and other settings could aid clinicians in rapidly making optimal patient disposition decisions. For patients who are hospitalized, it could guide the intensity of monitoring and the initial admission location (hospital ward, telemetry, or intensive care unit). If validated in the outpatient setting, it could also guide hospitalization decisions. Key risk factors for mortality have been identified and include increasing age, male sex, comorbidities, and certain laboratory parameters. Systematic review of laboratory parameters found that lymphopenia and elevated levels of c-reactive protein (CRP), neutrophil count, interleukin-6 (IL-6), d-dimer, lactate dehydrogenase (LDH), and troponin I were all associated with a poor outcome in hospitalized COVID-19 patients.
Researchers have attempted to develop prediction models for poor prognosis in COVID-19 patients, combining demographic, comorbidity, physical examination, laboratory, and imaging predictors into multivariate models. In some cases these have been simplified into clinical prediction rules (CPRs) or online calculators. However, many have not been externally validated, and none have been externally validated in a US population. In addition, many of these clinical prediction rules or models use laboratory tests and imaging that would not readily allow their extension to primary care or urgent care settings. As more COVID-19 patients are managed via telehealth, having a clinical prediction rule that can be applied early in the disease course and that does not rely on any laboratory testing would be desirable to avoid having to bring low risk patients to a laboratory or outpatient office for an in-person visit.

Therefore, the primary goal of the current study is to develop and validate two simple CPRs to predict COVID-19 mortality risk, one that relies only on non-laboratory parameters (COVID-NoLab), and another that adds simple laboratory tests commonly available in primary or urgent care settings (COVID-SimpleLab). As the goal is to decide decision-making on initial presentation, only data from the first 24 hours will be used to develop the CPRs. To accomplish this, we used data from a diverse multicenter US population of adults hospitalized with COVID-19. Secondarily, we will use this population’s data to evaluate several previously developed risk scores for COVID-19 prognosis.

**Methods and Materials**

**Study organization**

The lead investigator (MHE) identified colleagues at 6 major US universities (University of Wisconsin-Madison, Penn State University, University of Florida, Virginia Commonwealth...
University, University of California at Los Angeles, and Georgetown University) with inpatient health centers to participate in a study of COVID-19 prognosis. Each site obtained Institutional Review Board (IRB) approval for this project, which was deemed to be exempt research due to using de-identified, previously collected patient data extracted retrospectively from each health system’s electronic health record. Data use agreements were established between each university and the University of Georgia. The overall project was approved by the University of Georgia IRB.

Data collection
A standardized dataset of demographic, clinical, and laboratory parameters was assembled using extant literature and with input from the group (Appendix A). Comorbidities were defined using Clinical Classifications Software categories for the following disease clusters: cardiovascular disease (CCS 101), chronic obstructive pulmonary disease (CCS 127), asthma (CCS 128), and diabetes mellitus (CCS 49).\textsuperscript{13} Inclusion criteria included any adult inpatient with a positive polymerase chain reaction (PCR) test for COVID-19 hospitalized at one of the participating institutions whose disposition was already determined (discharged or deceased) at the time of data extraction. The primary outcome was in-hospital mortality. We also conducted exploratory analyses for prediction of the combined outcome of death or need for mechanical ventilation.

Each site was responsible for its own data extraction from their electronic health record, following the standardized approach to each variable definition. Gender, age and predictor variable were collected. Since the goal is to be able to predict prognosis at admission, only predictor variables available within 24 hours of admission date/time were included. Each patient’s extracted data were de-identified at the collection site. As age over 90 could be
considered identifying, patients aged 90 years or over had their age listed as 90. Each center had a different range of dates for data collection, beginning as early as March 1, 2020 and extending as far as June 12, 2020. Deidentified data were securely transferred from each institution to a central repository at the University of Georgia where they were combined for analysis.

Validation of existing clinical risk scores

The lead investigator’s systematic review of individual risk factors, risk scores and prognostic models to predict critical illness or death in patients with COVID-19 (manuscript in review) was used to identify two simple risk scores and a simple multivariate model for COVID-19 mortality in the literature (all in inpatients). For each patient with the predictor variables in the risk score, the score was calculated. The proportion of patients with the outcome of interest (e.g. death) in each risk group and where possible the area under the receiver operating characteristic curve were calculated for each score or model.

Development and internal validation of novel risk scores using our dataset

Continuous variables were presented as the median and interquartile range (IQRs), and categorical variables were presented as frequencies and percentages of occurrence. For the univariate analysis, the bivariate associations between predictor variables and mortality were assessed using the chi-square test for categorical variables and Wilcoxon rank-sum test for continuous variables.

We then randomly divided the data into derivation and validation groups with a ratio of 60:40 and built logistic regression models in the derivation set with in-hospital mortality as the outcome or dependent variable. In the first model, we only considered the patient’s age,
comorbidities, and vital signs (including oxygen saturation) as independent predictors. In the second model, we added the white blood cell count (WBC), white cell differential, serum creatinine, and c-reactive protein (CRP) to the models. Imputation of laboratory data was considered, but given the large number of missing cases we performed complete case analyses. Continuous variables were converted to categorical variables to simplify calculations in the final risk score based on inspection of histograms. We used stepwise backwards selection with \( p < 0.1 \) for retention in the model.\(^4\) Once the predictors were selected, beta coefficients were determined from the final multivariable logistic regression model. We then created a simple point score by dividing each beta coefficient by the smallest beta value and rounded it to the nearest integer. The low-risk, moderate-risk, and high-risk groups were created based on visual inspection of the point score distribution to create groups that would be most useful for clinical decision-making, with a particular goal of having the low risk group be at or near 1% mortality.

The performance of the point scores was internally validated using the validation dataset. This included evaluation of how accurately the score classified patients into low-, moderate-, and high-risk groups. We used the Hosmer-Lemeshow test and a calibration curve to evaluate calibration, which indicates how well predicted mortality matched observed mortality. The area under receiving operating characteristic curve (AUC) was used as a measure of overall discrimination.

**Results**

**Characteristics of the study population**

The characteristics of the study population are summarized in Table 1, stratified by health system. The number of patients available for analysis at each center ranged from 69 to 582,
and the mortality rate ranged from 1.4% to 16.7% with an overall mortality rate of 13.1%. The median age of participants at the six sites ranged from 52 to 62 years; there was a slight male preponderance.

The bivariate analysis of the association between clinical variables and mortality is shown in Table 2. Non-laboratory parameters positively associated with mortality (p < 0.05) included increasing age, several comorbidities (cardiovascular disease, diabetes mellitus, and chronic obstructive pulmonary disease), increased body mass index, decreased oxygen saturation and increased respiratory rate. Laboratory parameters positively associated with mortality included increased c-reactive protein, white blood cell (WBC) count, neutrophil count, and serum creatinine, and decreased lymphocyte count.

**Development and validation of simple risk scores**

Table 3 summarizes the two multivariate models to predict COVID-19 mortality using basic data available at initial presentation. Complete case data were available for 1342 patients for the COVID-NoLab model and 741 for the COVID-SimpleLab model. The COVID-NoLab model had an area under the receiver operating characteristic curve (AUROCC) of 0.771 in the derivation group and 0.803 in the validation group. The COVID-SimpleLab model had an AUROCC of 0.835 in the derivation group and 0.833 in the validation group.

Calibration in the validation groups was good based on visual inspection of calibration plots, with non-statistically significant values for the Hosmer-Lemeshow goodness of fit test (p = 0.759 for the COVID-NoLab model and p = 0.400 for the COVID-SimpleLab model). The ROC curves and calibration plots for each model are shown in Appendix B.
The COVID-NoLab and COVID-SimpleLab risk scores were created based on the derivation set data, using beta-coefficients as described above. The COVID-NoLab and COVID-SimpleLab risk scores and their classification accuracy are summarized in Table 4 for the derivation and validation groups for each risk score. Both simple risk scores had similar classification accuracy in the derivation and validation groups. However, the score that adds simple laboratory tests classifies a higher percentage of patients as low risk (29% vs 21% in derivation and 33% vs 24% in validation) who could potentially be managed as outpatients. It also classifies more patients as high risk who will require closer monitoring or intensive care (29% vs 12% in derivation and 34% vs 11% in validation).

Models were also developed and internally validated for settings where only the white blood cell count might be available, or only the c-reactive protein test. These models their risk scores are summarized in Appendix C. While both models were able to identify high risk patients, in each case the low risk group in the validation datasets had an appreciably higher mortality rate than in the derivation data (4.4% vs 0.0% for both models). Their calibration was good, based on visual inspection of the calibration plots and the Hosmer-Lemeshow test.

**Evaluation of previous risk scores**

We evaluated three existing simple models for predicting COVID-19 mortality. A total of five clinical variables were included in the three tools: age, CRP, lactate dehydrogenase, lymphopenia, and oxygen saturation. Two tools used classification trees and had not been externally validated and one was a simple multivariate model that had been validated at a single Chinese hospital. We were unable to evaluate the accuracy of other risk scores due to either the unavailability of some of the predictors in our dataset, or because they predicted...
outcomes other than mortality. The performance of each of the three prediction models in the US study population is summarized in Table 5.

**Discussion**

We have developed and internally validated two simple clinical prediction rules, one of which requires no laboratory testing (COVID-NoLab) and another that only require clinical variables plus simple laboratory tests that are commonly and rapidly available in many outpatient settings (COVID-SimpleLab). The score that includes simple lab tests classifies more patients as low or high risk and is therefore potentially more clinically useful. Previous risk scores have either not been internally validated, have not been validated in the United States, or have required tests not commonly available in outpatient settings such as procalcitonin, lactate dehydrogenase, or chest radiography. Our risk scores performed well in an internal validation, although external, prospective validation in other populations would be desirable. The risk scores are simple enough for clinicians to memorize or keep on a pocket card. In the future, they could be made available as a mobile app for point-of-care use or integrated into electronic health records.

The COVID-NoLab score has important potential utility in the telehealth setting, which has become a common venue for assessing and monitoring COVID-positive patients while minimizing the risk of viral transmission to clinical staff. While the score does require an oxygen saturation level, patients with COVID-19 are increasingly being given devices for home assessment of oxygen saturation as a way to remotely monitor their symptoms. Our study reinforces the value of knowing this parameter as a way to predict mortality risk and potentially health decline. Our findings, while not yet conclusive, may encourage innovative health systems to consider home oxygen saturation as a means to safely manage COVID-infected patients at home. For example, one could have patients measure oxygen saturation twice daily, have a
daily telehealth visit with a healthcare professional who could evaluate respiratory rate, and recalculate the risk score daily. It is also something that could be used by emergency response personnel when evaluating patients in the field, where blood tests are not available but oxygen saturation monitors are readily available.

The COVID-SimpleLab risk score was somewhat more accurate than the COVID-NoLab risk score, and is appropriate for outpatient settings where the white blood cell count, c-reactive protein, and serum creatinine are available. We also developed risk scores that included only clinical variables and either WBC or CRP, since outpatient settings around the world often have different tests available. For example, while the WBC is often available in the US primary care setting at the point of care, CRP is rarely available. On the other hand, the opposite is true in many European countries.\textsuperscript{16,17} While the “Clinical + WBC” and “Clinical + CRP” risk scores did not perform as well in validation, particularly at identifying a very low risk group, they should still be prospectively validated in lower risk outpatients with COVID-19 to see if they perform better in that population.

The previously reported risk scores originally developed in Chinese populations\textsuperscript{9,10,11} were less accurate in our US population. This may be because of overfitting of the early models, differences in the spectrum of illness, or differences between the healthcare systems in China and the United States. Also, these models were developed early in the pandemic when mortality rates were higher.

We hope to work with investigators at other institutions to evaluate the COVID-NoLab and COVID-SimpleLab models in their populations. We only gathered data on four comorbidities, and in the future would want to explore adding other clinical variables such as hypertension,
chronic liver disease, and tobacco use. It would be preferable to use prospective data collection and add patient symptoms such as dyspnea, although respiratory rate and oxygen saturation measurements may covary with dyspnea making it less important. Including patients identified in a range of settings and managed as outpatients will be important. Finally, this work should be ongoing, since as treatments will hopefully improve the prognosis will change and predictive models will require updating.

Strengths and Limitations

An important strength of this study is that our model was developed using data from six geographically diverse sites in the United States, sites that serve racially and ethnically diverse populations. Further, by generating risk scores that use either no laboratory variables or limited laboratory testing, if appropriately validated our results could potentially be useful in outpatient settings or in telehealth to guide decisions regarding the need for admission or the intensity of outpatient follow-up that is needed. The risk scores are also quite simple and have good face validity, making them practical for busy clinical settings.

Our study has several limitations. This is a convenience sample and we only included data for patients who had been discharged alive or who died. Thus, patients still in the hospital were not included; this may bias the sample. Importantly, the data collected is restricted to COVID-19 patients in an inpatient setting who have a narrower and more severe spectrum of illness than patients managed at home without hospitalization. Thus, our work requires validation in other populations including primary care and urgent care settings before clinical application in outpatients. Changes in the virus itself and changes in treatment may also affect prognosis over time, so any risk score may eventually require updating or recalibration. Finally, we used a split
sample internal validation which may inflate calibration, and the model should be prospectively validated prior to adoption by clinicians.

Conclusion

The COVID-NoLab and COVID-SimpleLab scores derived in a large, diverse population of hospitalized COVID-19 patients in the US had good discrimination, calibration, and classification accuracy using an internal validation (split sample) approach. If validated in a new population of hospitalized patients, they provide a rapid, simple way to determine prognosis for hospitalized patients and identify a low risk group that could be considered for outpatient management in a bed shortage, for example. Because they were designed to use no or minimal laboratory tests, these risk scores may also be generalizable to outpatient settings. This could potentially provide clinicians a useful aid for decision-making regarding hospital admission and the intensity of outpatient follow-up. However, it is important that the risk scores be prospectively validated in the outpatient setting before its use there.
Table 1. Characteristics of included patients from each institution

| Disposition          | Georgetown University (n=582) | Virginia Commonwealth University (n=223) | University of Wisconsin (n=102) | Penn State University (n=69) | University of Florida (n=133) | University of California LA (n=333) | Total (n=1442) |
|----------------------|-------------------------------|------------------------------------------|---------------------------------|-------------------------------|-------------------------------|-------------------------------------|----------------|
| Discharge home       | 485 (83.3%)                   | 190 (85.2%)                              | 88 (86.3%)                      | 68 (98.6%)                    | 121 (91%)                     | 301 (90.4%)                         | 1253 (86.9%) |
| Deceased             | 97 (16.7%)                    | 33 (14.8%)                               | 14 (13.7%)                      | 1 (1.4%)                      | 12 (9%)                       | 32 (9.6%)                           | 189 (13.1%)|
| Demographics and     |                              |                                          |                                 |                               |                               |                                     |                |
| vitals               |                              |                                          |                                 |                               |                               |                                     |                |
| Age: median          | 61 (22)                       | 61 (22)                                  | 62 (25)                         | 63 (29)                       | 57 (39)                       | 52 (30)                             | 61 (25)        |
| (interquartile range)|                              |                                          |                                 |                               |                               |                                     |                |
| Male: Female         | 287:295                       | 119:104                                  | 55:47                           | 34:35                         | 53:80                         | 197:143                             | 745:704       |
Table 2. Association between individual clinical variables and the outcome of mortality.

| Clinical predictors                                      | Discharged Alive | Deceased | p-value   |
|----------------------------------------------------------|------------------|----------|-----------|
| **Categorical variable (n [%])**                         |                  |          |           |
| Female sex                                               | 615 (49.1)       | 84 (44.4)| 0.267     |
| Chronic obstructive pulmonary disease                    | 180 (14.4)       | 44 (23.3)| 0.002     |
| Asthma                                                   | 139 (11.1)       | 23 (12.2)| 0.754     |
| Diabetes                                                 | 421 (33.6)       | 91 (48.1)| <0.001    |
| Cardiovascular disease                                   | 217 (17.3)       | 56 (29.6)| <0.001    |
| Temperature ≥ 39 °C                                      | 69 (5.8)         | 11 (6.0 )| 1         |
| Temperature ≥ 38 °C                                      | 203 (17.0)       | 34 (18.6)| 0.684     |
| Age (years)                                              |                  |          |           |
| <50                                                      | 396 (32.3)       | 9 (5)    |           |
| 50 to 65                                                 | 415 (33.8)       | 42 (23.2)|           |
| 66-79                                                    | 270 (22)         | 79 (43.7)|           |
| >80                                                      | 146 (11.9)       | 51 (28.1)|           |
| Body mass index >=40 kg/m2                               | 147 (14.0)       | 27 (15.9)| 0.604     |
| Body mass index >=30 kg/m2                               | 513 (49.0)       | 69 (40.6)| 0.051     |
| Oxygen saturation < 93%                                  | 82 (7.0)         | 36 (19.3)| <0.001    |
| Respiratory rate ≥ 25 breaths/minute                     | 215 (17.9)       | 67 (35.6)| <0.001    |
| Respiratory rate ≥ 30 breaths/minute                     | 96 (8.0)         | 40 (21.3)| <0.001    |
| C-reactive protein                                       |                  |          |           |
| > 10 mg/dL                                               | 228 (33.0)       | 77 (67.5)| <0.001    |
| > 15 mg/dL                                               | 119 (17.2)       | 46 (40.4)| <0.001    |
| > 20 mg/dL                                               | 42 (6.1)         | 15 (13.2)| 0.011     |
| > 40 mg/dL                                               | 2 (0.3)          | 2 (1.8) | 0.18      |
| White blood cell count > 10 x 10⁹/ml                     | 172 (14.9)       | 60 (33.0)| <0.001    |
| Lymphocytes < 0.8 x 10⁹/ml                               | 271 (26.0)       | 68 (40.5)| <0.001    |
| Neutrophils > 8 x 10⁹/ml                                 | 145 (13.9)       | 49 (29.2)| <0.001    |
| Serum creatinine >= 2.0 mg/dl                            | 114 (9.9)        | 66 (36.1)| <0.001    |
| **Continuous variables (median [IQR])**                  |                  |          |           |
| Age in years                                             | 59 [44.5, 71]    | 72.5 [64.8, 80] | <0.001 |
| Temperature °C                                            | 37.2 [36.8, 37.8]| 37.2 [36.8, 37.8] | 0.831 |
| Oxygen saturation                                          | 97% [95%, 98%]   | 95% [93%, 97%] | <0.001 |
| Respiratory rate (breaths/minute)                         | 20 [18, 23]      | 20 [18, 27] | <0.001 |
| White blood cell count (x 10⁹/ml)                         | 6.1 [4.6, 8.1]   | 7.5 [5.5, 11.8] | <0.001 |
| Lymphocytes (x 10⁹/ml)                                    | 1.1 [0.8, 1.5]   | 0.8 [0.6, 1.3] | <0.001 |
| Neutrophils (x 10⁹/ml)                                    | 4.4 [3.6, 2.2]   | 5.9 [4.8, 7.7] | <0.001 |
| Test                                | Group 1       | Group 2       | p-value |
|-------------------------------------|---------------|---------------|---------|
| Body mass index (kg/m²)             | 29.8 [25.3, 35.8] | 28.5 [24.6, 35.8] | 0.254   |
| Serum creatinine (mg/dl)            | 0.9 [0.8, 1.3]    | 1.5 [1.1, 2.7]    | <0.001  |
| C-reactive protein (mg/dL)          | 6.2 [2.4, 12.3]    | 13 [9, 17.3]     | <0.001  |
| Lactate dehydrogenase (U/L)         | 313 [241, 409]    | 441 [349, 590]    | <0.001  |
Table 3. Multivariate models using limited clinical data to predict mortality in hospitalized patients with COVID-19

| Predictors                          | β-coefficient | Std. Error | Z value | Pr(>|z|) |
|-------------------------------------|---------------|------------|---------|----------|
| **Model using no laboratory values (COVID-NoLab)** |               |            |         |          |
| Constant                            | -4.010        | 0.465      | -8.620  | 0.001    |
| Age                                 |               |            |         |          |
| 50 to 65 years                      | 1.631         | 0.498      | 3.270   | 0.001    |
| > 65 years                          | 2.602         | 0.478      | 5.450   | < 0.001  |
| Respiratory rate ≥ 30 / min         | 1.352         | 0.293      | 4.620   | < 0.001  |
| Oxygen saturation < 93%             | 1.036         | 0.288      | 3.600   | < 0.001  |
| AUROCC = 0.771 in the derivation group and 0.803 in the validation group. |

| Predictors                          | β-coefficient | Std. Error | Z value | Pr(>|z|) |
|-------------------------------------|---------------|------------|---------|----------|
| **Model adding simple blood tests (COVID-SimpleLab)** |               |            |         |          |
| Constant                            | -4.899        | 0.669      | -7.330  | 0.000    |
| C-reactive protein                  |               |            |         |          |
| 11 – 20 mg/dL                       | 1.316         | 0.329      | 4.010   | 0.000    |
| > 20 mg/dL                          | 1.057         | 0.510      | 2.080   | 0.038    |
| Respiratory rate ≥ 30 / min         | 1.522         | 0.403      | 3.770   | 0.000    |
| Oxygen saturation < 93%             | 0.911         | 0.418      | 2.180   | 0.029    |
| Age                                 |               |            |         |          |
| 50 to 65 years                      | 1.310         | 0.661      | 1.980   | 0.047    |
| > 65 years                          | 2.233         | 0.640      | 3.490   | 0.000    |
| Asthma                              | 0.953         | 0.428      | 2.230   | 0.026    |
| White blood cell count > 10 x 10⁹/ml | 0.579         | 0.348      | 1.660   | 0.097    |
| Serum creatinine > 2.0 mg/dl        | 1.152         | 0.348      | 3.310   | 0.001    |
| AUROCC = 0.835 in the derivation group and 0.833 in the validation group. |
Table 4. Calculation of the COVID-SimpleNoLab and COVID-SimpleLab risk scores and their classification accuracy in derivation and validation groups.

| Clinical predictor | Points | Risk Group | Derivation Group | Validation group |
|--------------------|--------|------------|------------------|------------------|
| Age                |        |            | Mortality        | Mortality        |
|                    |        | Low (0-1)  | n/total (%)      | SSLR             |
|                    |        | 3/167 (1.8%) | 0.10            | 1/129 (0.8%)     | 0.06             |
| Age                |        | Moderate (2-5) | 74/543 (13.6%)  | 0.89            | 40/350 (11.4%)   | 0.95             |
| Age                |        | High (6+)  | 44/96 (45.8%)   | 4.79            | 23/57 (40.4%)    | 4.99             |
| Respiratory rate ≥ 30 | 3 | Low (0-7)  | 0/129 (0.0%)    | 0.00            | 1/97 (1.0%)      | 0.07             |
| Respiratory rate ≥ 30 | 5 | Moderate (8 to 11) | 10/131 (8.3%) | 0.46            | 9/99 (9.1%)      | 0.66             |
| O₂ saturation < 93% | 4 | High (12+) | 58/185 (45.7%)  | 2.53            | 29/99 (29.3%)    | 2.73             |
| Age                |        | Low (0-7)  | 0/129 (0.0%)    | 0.00            | 1/97 (1.0%)      | 0.07             |
| Age                |        | Moderate (8 to 11) | 10/131 (8.3%) | 0.46            | 9/99 (9.1%)      | 0.66             |
| O₂ saturation < 93% | 4 | High (12+) | 58/185 (45.7%)  | 2.53            | 29/99 (29.3%)    | 2.73             |
| Age                |        | Low (0-7)  | 0/129 (0.0%)    | 0.00            | 1/97 (1.0%)      | 0.07             |
| Age                |        | Moderate (8 to 11) | 10/131 (8.3%) | 0.46            | 9/99 (9.1%)      | 0.66             |
| O₂ saturation < 93% | 4 | High (12+) | 58/185 (45.7%)  | 2.53            | 29/99 (29.3%)    | 2.73             |

SSLR = stratum specific likelihood ratio
Table 5. Selected clinical prediction rules for COVID-19 prognosis. See Appendix for details regarding calculation of risk scores.

| Study      | Performance in original study | Performance in 5 US sites     |
|------------|-------------------------------|-------------------------------|
| Lu, 2020   | Low risk: 0%                   | Low risk: 2/108 (1.8%)        |
|            | Mod risk: 6%                   | Moderate risk: 24/359 (6.7%)  |
|            | High risk: 33%                 | High risk: 87/324 (26.9%)     |
| Xie, 2020  | AUC (derivation) = 0.893       | AUC = 0.7981                  |
|            | AUC (test) = 0.980             | Hosmer-Lemeshow p = 0.23      |
| Yan, 2020  | Low risk: 3/189 (1.6%)         | Low risk: 10/243 (4.1%)       |
|            | High risk: 157/162 (96.9%)     | High risk: 85/374 (22.7%)     |

AUC = area under the receiver operating characteristic curve
References Cited

1. Johns Hopkins COVID-19 Dashboard. https://coronavirus.jhu.edu/map.html. Accessed June 27, 2020.

2. Stringhini S, Wisniak A, Piumatti G, et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study. Lancet. 2020. doi:10.1016/s0140-6736(20)31304-0

3. Verity R, Okell LC, Dorigatti I, et al. Estimates of the severity of coronavirus disease 2019: a model-based analysis. Lancet Infect Dis. 2020. doi:10.1016/S1473-3099(20)30243-7

4. Wu C, Chen X, Cai Y, et al. Risk Factors Associated with Acute Respiratory Distress Syndrome and Death in Patients with Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med. 2020. doi:10.1001/jamainternmed.2020.0994

5. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020. doi:10.1016/S0140-6736(20)30566-3

6. Fu L, Wang B, Yuan T, et al. Clinical characteristics of coronavirus disease 2019 (COVID-19) in China: A systematic review and meta-analysis. J Infect. 2020. doi:10.1016/j.jinf.2020.03.041

7. Moutchia J, Pokharel P, Kerri A, et al. Clinical Laboratory Parameters Associated with Severe or Critical Novel Coronavirus Disease 2019 (COVID-19): A Systematic Review and Meta-analysis. medrxiv.org. 2020. doi:https://doi.org/10.1101/2020.04.24.20078782

8. Liang W, Liang H, Ou L. Development and Validation of a Clinical Risk Score to Predict the Occurrence of Critical Illness in Hospitalized Patients With COVID-19. JAMA Intern Med. 2020. doi:10.1001/jamainternmed.2020.2033

9. Lu J, Hu S, Fan R, et al. Preprint: ACP risk grade: a simple mortality index for patients
with confirmed or suspected severe acute respiratory syndrome coronavirus 2 disease (COVID-19) during the early stage of outbreak in Wuhan. medRxiv.org. 2020.
doi:https://doi.org/10.1101/2020.02.20.20025510

10. Xie J, Hungerford D, Chen H, Abrams ST. Preprint: Development and external validation of a prognostic multivariable model on admission for hospitalized patients with COVID-19. medrxiv.org. 2020. doi:https://doi.org/10.1101/2020.03.28.20045997

11. Yan L, Zhang H-T, Xiao Y, Wang M. Preprint: Prediction of criticality in patients with severe Covid-19 infection using three clinical features. medrxiv.org. 2020.
doi:https://doi.org/10.1101/2020.02.27.20028027

12. Galloway JB, Norton S, Barker RD, et al. A clinical risk score to identify patients with COVID-19 at high risk of critical care admission or death: An observational cohort study. J Infect. 2020. doi:10.1016/j.jinf.2020.05.064

13. AHRQ HCUP Web site.

14. Hocking RR. The analysis and selection of variables in linear regression. Biometrics. 1976. doi:10.2307/2529336

15. Xie J, Hungerford D, Chen H, et al. Development and External Validation of a Prognostic Multivariable Model on Admission for Hospitalized Patients with COVID-19. SSRN Electron J. 2020. doi:10.2139/ssrn.3562456

16. Hardy V, Thompson M, Keppel GA, et al. Qualitative study of primary care clinicians’ views on point-of-care testing for C-reactive protein for acute respiratory tract infections in family medicine. BMJ Open. 2017;7(1):e012503. doi:10.1136/bmjopen-2016-012503

17. Howick J, Cals JWL, Jones C, et al. Current and future use of point-of-care tests in primary care: An international survey in Australia, Belgium, The Netherlands, the UK and the USA. BMJ Open. 2014. doi:10.1136/bmjopen-2014-005611
### Appendix A: Full list of requested clinical variables. Predictor variables only included if ordered within 24 hours of admission

| Clinical variable                        | Normal range      | Units              |
|-----------------------------------------|-------------------|--------------------|
| **Demographics**                        |                   |                    |
| Health system                           |                   |                    |
| Hospital                                |                   |                    |
| Age in years                            |                   | Years              |
| Sex                                     |                   |                    |
| Race                                    |                   |                    |
| **Comorbidities**                       |                   |                    |
| COPD                                    |                   |                    |
| Asthma                                  |                   |                    |
| Cardiovascular disease                  |                   |                    |
| Hypertension                            |                   |                    |
| Diabetes mellitus                       |                   |                    |
| **Vitals**                              |                   |                    |
| Respiratory rate                        | 12 to 20          | breaths/minute     |
| Temperature                             | 36.5 to 37.5      | degrees Celsius    |
| Heart rate                              | 60 to 100         | beats/minute       |
| Systolic blood pressure                 | 90 to 139         | mm Hg              |
| Diastolic blood pressure                | 50 to 89          | mm Hg              |
| BMI                                     | 20 to 24.9        | kg/m2              |
| O2 saturation room air                  | 95% to 100%       | %                  |
| **Laboratory tests**                    |                   |                    |
| White blood cell count                  | 4.5 to 10         | 1000 cells/microliter |
| Lymphocyte count                        | 1000 to 4800      | cells/microliter   |
| Neutrophil count                        | 2500 to 7500      | cells/microliter   |
| Platelets                               | 150,000 to 450,000 | platelets/microliter |
| Serum creatinine                        | 0.5 to 1.2        | mg/dl              |
| Blood urea nitrogen                     | 7 to 20           | mg/dl              |
| Lactate dehydrogenase (LDH)             | 140 to 280        | units/liter        |
| Test                                | Range      | Unit          |
|------------------------------------|------------|---------------|
| Aspartate aminotransferase (AST)   | 10 to 40   | units/liter   |
| Alanine aminotransferase (ALT)     | 7 to 56    | units/liter   |
| Ferritin                           | 12 to 300  | ng/ml         |
| Troponin T or I                    | 0 to 0.4   | ng/ml         |
| C-reactive protein (CRP)           | < 10       | mg/dl         |
| D-dimer                            | < 0.5      | mg/liter      |
| Interleukin-6 (IL6)                | 0 to 16    | pg/ml         |

**Outcome variables**

- Vasopressor needed in first 24 hours
- Discharge disposition (discharged home, still hospitalized, deceased)
- ICU admit during hospitalization (Y/N)
- Mechanical ventilation (Y/N)
- Number of days hospitalized (including observation status)
- Number of days in the ICU
- Number of days on ventilator
APPENDIX B

Model using clinical predictors only (COVID-NoLab)

Derivation dataset

ROC curve

Calibration plot

number of observations = 1343
number of groups = 5
Hosmer-Lemeshow chi2(3) = 2.34

© Copyright 2020 by the American Board of Family Medicine.
Prob > chi2 = 0.5051

Validation dataset

ROC curve

Area under ROC curve = 0.8033

Calibration plot

number of observations = 537
number of groups = 7
Hosmer-Lemeshow chi2(5) = 2.62
Prob > chi2 = 0.7590

© Copyright 2020 by the American Board of Family Medicine.
Ahead-of-print; non-copy edited version.
Model using clinical + CBC + CRP + creatinine (COVID-SimpleLab)

Derivation dataset

ROC curve

![ROC Curve Diagram]

Calibration plot

![Calibration Plot Diagram]

number of observations = 445
number of groups = 10
Hosmer-Lemeshow chi2(8) = 10.07
Prob > chi2 = 0.2601
Validation dataset

ROC curve

Calibration plot

number of observations = 295
number of groups = 9
Hosmer-Lemeshow chi2(7) = 7.29
Prob > chi2 = 0.3998

© Copyright 2020 by the American Board of Family Medicine.
Ahead-of-print; non-copy edited version.
APPENDIX C

Model using clinical variables + CBC only

Logistic Regression Model

|                  | Coef.  | Std. Err. | z     | P>|z| | Points |
|------------------|--------|-----------|-------|-----|--------|
| WBC > 10         | 0.586  | 0.279     | 2.100 | 0.036| 1      |
| Resp rate ≥ 30   | 1.404  | 0.344     | 4.080 | 0.000| 2      |
| O₂ sat < 93%     | 0.986  | 0.337     | 2.930 | 0.003| 2      |
| Age              |        |           |       |     |        |
| 50 to 65         | 3.101  | 1.031     | 3.010 | 0.003| 5      |
| > 65             | 4.179  | 1.020     | 4.100 | 0.000| 7      |
| _cons            | -5.699 | 1.018     | -5.600| 0.000|        |

Proposed point score and its accuracy for prediction of mortality in development and validation datasets.

| Development |       |       |       |       |       |
|-------------|-------|-------|-------|-------|-------|
| Risk group  | Deaths| Survivors| Total| Mortality| LR   |
| (points)    |       |         |      |          |      |
| Low: 0 to 2 | 0     | 163     | 163  | 0.0%     | 0.00 |
| Mod: 3 to 6 | 20    | 192     | 212  | 10.4%    | 0.65 |
| High: 7+    | 77    | 254     | 331  | 30.3%    | 1.90 |
|             | 97    | 609     | 706  |          |      |

| Validation  |       |       |       |       |       |
|-------------|-------|-------|-------|-------|-------|
| Risk group  | Deaths| Survivors| Total| Mortality| LR   |
| (points)    |       |         |      |          |      |
| Low: 0 to 2 | 5     | 108     | 113  | 4.4%     | 0.27 |
| Mod: 3 to 6 | 6     | 113     | 119  | 5.0%     | 0.31 |
| High: 7+    | 58    | 180     | 238  | 24.4%    | 1.87 |
|             | 69    | 401     | 470  |          |      |
Derivation dataset

ROC curve

[Graph showing the ROC curve with the area under the curve (AUC) labeled as 0.7761]

Calibration plot

[Graph showing the calibration plot with the observed and predicted proportions plotted]

number of observations = 706
number of groups = 7
Hosmer-Lemeshow chi2(5) = 4.61
Prob > chi2 = 0.4649
Validation dataset

ROC curve

Calibration plot

number of observations = 470
number of groups = 8
Hosmer-Lemeshow chi2(6) = 5.30
Prob > chi2 = 0.5055
Model using clinical predictors + CRP only

|                | Coef.  | Std. Err. |   z  | P>z   | Points |
|----------------|--------|-----------|------|-------|--------|
| CRP            |        |           |      |       |        |
| > 10 to 20 mg/dl | 1.522  | 0.309     | 4.920| 0.000 | 3      |
| > 20 mg/dl     | 0.974  | 0.539     | 1.810| 0.071 | 2      |
| Respiratory rate ≥ 30 | 1.246  | 0.420     | 2.970| 0.003 | 3      |
| Age            |        |           |      |       |        |
| 50 to 65       | 1.798  | 0.786     | 2.290| 0.022 | 4      |
| > 65           | 3.279  | 0.765     | 4.290| 0.000 | 7      |
| Asthma         | 0.977  | 0.417     | 2.340| 0.019 | 2      |
| _cons          | -5.236 | 0.782     | -6.690| 0.000 |        |

TRAINING

| Risk group | Deaths | Survivors | Total | Prev  | LR  |
|------------|--------|-----------|-------|-------|-----|
| 0 to 4     | 3      | 176       | 179   | 1.7%  | 0.10|
| 5 to 8     | 21     | 157       | 178   | 11.8% | 0.76|
| 9+         | 47     | 71        | 118   | 39.8% | 3.77|
|            | 71     | 404       | 475   |       |     |

TESTING

| Risk group | Deaths | Survivors | Total | Prev  | LR  |
|------------|--------|-----------|-------|-------|-----|
| 0 to 4     | 5      | 108       | 113   | 4.4%  | 0.30|
| 5 to 8     | 11     | 115       | 126   | 8.7%  | 0.62|
| 9+         | 26     | 51        | 77    | 33.8% | 3.33|
|            | 42     | 274       | 316   |       |     |
Derivation dataset

ROC curve

Area under ROC curve = 0.8211

Calibration plot

number of observations = 475
number of groups = 9
Hosmer-Lemeshow chi2(7) = 1.62
Prob > chi2 = 0.9777
Validation dataset

ROC curve

Area under ROC curve = 0.7876

Calibration plot

number of observations = 316
number of groups = 9
Hosmer-Lemeshow chi2(7) = 1.73
Prob > chi2 = 0.9733